Stephen V Liu, MD
@StephenVLiu
Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Host @IASLC Podcast; Chair #DCLung24 #TexasLung24 #HereWeGo
ID:377425889
https://www.medstarhealth.org/doctors/stephen-liu-md 21-09-2011 15:17:53
17,3K Tweets
24,0K Followers
3,0K Following
Follow People
Decoding #Biomarkers and #TargetedTherapy in #NSCLC with Stephen V Liu, MD, Benjamin Levy, JessicaJLinMD & Solange Peters live in person & online during #ASCO24 on June 1 at 6:30 PM CDT. Produced with LUNGevity Foundation bit.ly/2024BiomarkersT
Does targeting #MET signaling enhance anti-tumor immune responses? Single arm trial of capmatinib + nivolumab in pts with NSCLC post-chemotherapy Lung Cancer Journal showed in high-MET, RR 25% with 6m PFS 69% and in low-MET, RR 16.7% with 6m PFS 51%.
lungcancerjournal.info/article/S0169-…
Update from phase 3 IMscin001 trial JTO & JTO CRR. Pts with NSCLC randomized 2:1 to subcutaneous vs IV atezolizumab. Similar OS (10.7 vs 10.1m) and safety. Subcutaneous typically took 4-8 minutes; felt more convenient, with higher satisfaction scores.
jto.org/article/S1556-…
Interesting multi-omic analysis of previously classified SCLC cell lines (YAP1+), identifies that these tumors represent diseases that ‘mimic’ SCLC- in this case- SMARCA4-deficient thoracic tumors, that have a poor prognosis
Clinical Cancer Research OncoAlert #LCSM
aacrjournals.org/clincancerres/…
On 10 May at Istituto Tumori and online for the second edition of the 'AI for Oncology' conference, we will explore how AI is transforming cancer. Under the auspices of ASCO, IASLC and AIOM. registrations to the event are still accepted @ aiforoncology.it ! #AI4Oncology
Join us tomorrow, May 8, 2024 (1-2 PM EDT/7-8 PM CET), for an educational webinar on the treatment of thymic tumors, featuring Drs. Mara Antonoff (Mara Antonoff, MD, FACS), Stephen Chun, and Chul Kim (@chulkimMD).
➡️Registration: bit.ly/44fL32J
ITMIG Society
Nice session of presentations and discussions this morning at #RomeLung24 on lung cancer IO and ADCs…impressive number of KOLs to discuss and exchange...so many questions about strategies for our patients !
Great overview of resistance mechanisms to #KRAS inhibitors in #NSCLC at #RomeLung24 by AmbrogioLab. Different therapeutic vulnerabilities depending on whether resistance is intrinsic, acquired, or adaptive.